- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 1.50 Å
- Oligo State
- homo-dimer
- Ligands
- 2 x ZN: ZINC ION(Non-covalent)
- 8 x MG: MAGNESIUM ION(Non-covalent)(Non-functional Binders)
MG.2: 3 residues within 4Å:- Chain A: D.125
- Ligands: ZN.1, T3K.24
6 PLIP interactions:1 interactions with chain A, 5 Ligand-Water interactions- Metal complexes: A:D.125, H2O.2, H2O.5, H2O.5, H2O.5, H2O.10
MG.3: 0 residues within 4Å:- (No contacts)
No protein-ligand interaction detected (PLIP)MG.4: 1 residues within 4Å:- Chain A: N.175
No protein-ligand interaction detected (PLIP)MG.5: 2 residues within 4Å:- Chain A: D.225, D.229
5 PLIP interactions:2 interactions with chain A, 3 Ligand-Water interactions- Metal complexes: A:D.225, A:D.229, H2O.1, H2O.4, H2O.8
MG.6: 0 residues within 4Å:- (No contacts)
No protein-ligand interaction detected (PLIP)MG.26: 2 residues within 4Å:- Chain B: D.125
- Ligands: ZN.25
6 PLIP interactions:1 interactions with chain B, 5 Ligand-Water interactions- Metal complexes: B:D.125, H2O.16, H2O.18, H2O.19, H2O.20, H2O.22
MG.27: 1 residues within 4Å:- Chain B: D.258
No protein-ligand interaction detected (PLIP)MG.28: 1 residues within 4Å:- Chain B: H.302
No protein-ligand interaction detected (PLIP)- 28 x EDO: 1,2-ETHANEDIOL(Non-functional Binders)
EDO.7: 2 residues within 4Å:- Chain A: N.133, Q.134
Ligand excluded by PLIPEDO.8: 4 residues within 4Å:- Chain A: K.186, I.189, D.190
- Chain B: N.148
Ligand excluded by PLIPEDO.9: 1 residues within 4Å:- Chain A: T.213
Ligand excluded by PLIPEDO.10: 4 residues within 4Å:- Chain A: K.284, H.285, N.286, A.287
Ligand excluded by PLIPEDO.11: 5 residues within 4Å:- Chain A: S.132, F.264, S.279, P.280, C.282
Ligand excluded by PLIPEDO.12: 3 residues within 4Å:- Chain A: D.75, H.76
- Ligands: EDO.13
Ligand excluded by PLIPEDO.13: 2 residues within 4Å:- Chain A: H.76
- Ligands: EDO.12
Ligand excluded by PLIPEDO.14: 3 residues within 4Å:- Chain A: N.138, R.274, M.276
Ligand excluded by PLIPEDO.15: 3 residues within 4Å:- Chain A: A.159, V.160
- Chain B: M.146
Ligand excluded by PLIPEDO.16: 4 residues within 4Å:- Chain A: Q.251, R.254, Q.255, D.258
Ligand excluded by PLIPEDO.17: 5 residues within 4Å:- Chain A: H.29, V.30, F.31, R.32, L.252
Ligand excluded by PLIPEDO.18: 4 residues within 4Å:- Chain A: M.281, G.295, F.296
- Ligands: T3K.24
Ligand excluded by PLIPEDO.19: 4 residues within 4Å:- Chain A: A.107, V.108, F.109, T.110
Ligand excluded by PLIPEDO.20: 8 residues within 4Å:- Chain A: P.103, A.104, S.219, G.220, V.312, H.313, P.314, D.315
Ligand excluded by PLIPEDO.21: 6 residues within 4Å:- Chain A: S.150, S.151, N.155, L.193
- Chain B: S.150
- Ligands: EDO.23
Ligand excluded by PLIPEDO.22: 4 residues within 4Å:- Chain A: F.6, T.48, Q.51, E.52
Ligand excluded by PLIPEDO.23: 4 residues within 4Å:- Chain A: S.150, S.151, K.199
- Ligands: EDO.21
Ligand excluded by PLIPEDO.29: 4 residues within 4Å:- Chain A: N.148
- Chain B: K.186, I.189, D.190
Ligand excluded by PLIPEDO.30: 4 residues within 4Å:- Chain B: D.22, K.25, W.26, G.27
Ligand excluded by PLIPEDO.31: 3 residues within 4Å:- Chain B: A.205, D.206, T.209
Ligand excluded by PLIPEDO.32: 4 residues within 4Å:- Chain B: H.78, D.80, V.81, P.129
Ligand excluded by PLIPEDO.33: 4 residues within 4Å:- Chain B: P.129, V.131, L.136, R.270
Ligand excluded by PLIPEDO.34: 2 residues within 4Å:- Chain B: D.321, D.325
Ligand excluded by PLIPEDO.35: 2 residues within 4Å:- Chain B: K.208, P.303
Ligand excluded by PLIPEDO.36: 2 residues within 4Å:- Chain B: H.313, P.314
Ligand excluded by PLIPEDO.37: 5 residues within 4Å:- Chain B: D.190, L.193, A.194, K.199, Q.235
Ligand excluded by PLIPEDO.38: 4 residues within 4Å:- Chain B: A.107, V.108, F.109, T.110
Ligand excluded by PLIPEDO.39: 7 residues within 4Å:- Chain B: H.29, V.30, F.31, R.32, Q.251, L.252, Q.255
Ligand excluded by PLIP- 2 x T3K: 3-[(~{E})-1-(3-cyclopentyloxy-4-methoxy-phenyl)ethylideneamino]oxy-1-morpholin-4-yl-propan-1-one(Covalent)(Non-covalent)
T3K.24: 18 residues within 4Å:- Chain A: Y.83, H.84, T.195, M.197, D.242, L.243, N.245, W.256, T.257, I.260, M.261, F.264, M.281, S.292, Q.293, F.296
- Ligands: MG.2, EDO.18
8 PLIP interactions:8 interactions with chain A- Hydrophobic interactions: A:L.243, A:F.264, A:M.281, A:F.296, A:F.296, A:F.296
- Hydrogen bonds: A:Q.293
- Water bridges: A:M.197
T3K.40: 12 residues within 4Å:- Chain B: Y.83, L.243, N.245, W.256, T.257, I.260, M.261, F.264, M.281, S.292, Q.293, F.296
6 PLIP interactions:6 interactions with chain B- Hydrophobic interactions: B:L.243, B:I.260, B:F.264, B:F.296
- Hydrogen bonds: B:Q.293
- pi-Stacking: B:F.296
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Brullo, C. et al., Design, synthesis, biological evaluation and structural characterization of novel GEBR library PDE4D inhibitors. Eur.J.Med.Chem. (2021)
- Release Date
- 2021-06-30
- Peptides
- cAMP-specific 3',5'-cyclic phosphodiesterase 4D: AB
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
B
- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 1.50 Å
- Oligo State
- homo-dimer
- Ligands
- 2 x ZN: ZINC ION(Non-covalent)
- 8 x MG: MAGNESIUM ION(Non-covalent)(Non-functional Binders)
- 28 x EDO: 1,2-ETHANEDIOL(Non-functional Binders)
- 2 x T3K: 3-[(~{E})-1-(3-cyclopentyloxy-4-methoxy-phenyl)ethylideneamino]oxy-1-morpholin-4-yl-propan-1-one(Covalent)(Non-covalent)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Brullo, C. et al., Design, synthesis, biological evaluation and structural characterization of novel GEBR library PDE4D inhibitors. Eur.J.Med.Chem. (2021)
- Release Date
- 2021-06-30
- Peptides
- cAMP-specific 3',5'-cyclic phosphodiesterase 4D: AB
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
B